Sab biotherapeutics announces progress on u.s. fda's phased review of company's groundbreaking diversitab™ platform

- fda has approved five of seven sections in a rolling submission required for a new animal drug application (nada) for company's antibody generating diversitab™ platform in transchromosomic (tc) bovine™

SABS Ratings Summary

SABS Quant Ranking